Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen.

Abstract

Ten patients with disseminated cancer were given i.v. injections of 0.2 ml/kg (40 mg I/kg) of the experimental contrast material EOE [Ethiodized Oil Emulsion] 13. CT [computed tomography] scans of the liver and spleen were taken prior to and 30 min after contrast infusion. Visualization of the liver was significantly improved in 5, moderately improved in 3 and not appreciably improved in 2. The spleen showed an obvious increase in density in all cases. No significant toxicity was encountered: untoward side effects consisted of fever, headaches, foul metallic taste and weakness for a short period. Four patients had no side effects and 2 experienced only abnormal taste sensation. Further experimental and clinical work is needed before the advantages and safety of this contrast material can be documented.